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Carney complex is an autosomal dominant disease that is clinically characterized by cardiac myxomas, spotty skin
pigmentation, and endocrine overactivity. Carney complex is most commonly caused by mutations in the PRKAR1A
gene on chromosome 17q22-24. Currently, there are at least 117 pathogenic mutations in PRKAR1A that have been
identified. Herein, we report on two cases of Carney complex in related Chinese patients with a c.491_492delTG
mutation that presented with multiple and extensive cardiac myxomas and skin pigmentation.
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Carney complex was initially described by J. Aiden
Carney in 1985. It is an autosomal dominant disorder
characterized by myxomas, spotty pigmentation, and
endocrine overactivity. The initial diagnosis of Carney
complex is based on clinical criteria and can be con-
firmed using genetic testing. The genetic tests have a
mutation detection rate of approximately 60% in pa-
tients with Carney complex. There are 12 clinical cri-
teria that are the major diagnostic indicators of Carney
complex. In addition, there are two supplemental diag-
nostic criteria that pertain to genetic testing and family
history [1,2].
The genetic disease Carney complex includes two
distinct syndromes: LAMB syndrome (lentigines, atrial
myxomas, mucocutaneous myxomas, and blue nevi)
and NAME syndrome (nevi, atrial myxoma, myxoid
neurofibroma, and ephelides). These are autosomal
dominant conditions that comprise myxomas in the
heart and skin, skin hyperpigmentation (lentiginosis),
and endocrine-related overactivity or tumors [1]. Carney
complex is most commonly caused by mutations in the* Correspondence: xujianpingmedsci@163.com
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unless otherwise stated.PRKAR1A gene on chromosome 17q22-24 [3]. It is less
commonly caused by a variety of genetic changes on
chromosome 2p16. Currently, 117 different PRKAR1A
mutations have been identified [4-7]. Herein, we identify
two Chinese Carney complex patients that are siblings
with a 491_492delTG PRKAR1A gene mutation. The pa-
tients presented with multiple and extensive cardiac myx-
omas and skin pigmentation.Case presentation
Case report 1
The first patient is a 14-year-old male who was admit-
ted to Fuwai Hospital, Beijing, in March 2012 with
intermittent syncope that had been ongoing over 2
years. Echocardiography showed multiple cardiac myx-
omas in the left atrium, left ventricle, and right ven-
tricle (Figure 1A,B). The cardiac myxomas in the left
atrium, left ventricle, and right ventricle were con-
firmed by MRI examination (Figure 2). Upon physical
examination, the patient had spotty skin pigmentation
on his face (Figure 3). The results of further evalua-
tions are presented in Table 1.
The patient underwent surgery on 9 March 2012.
The surgeon performed a median sternotomy andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Identification of cardiac myxomas by echocardiogram. (A) Patient 1 - pre-operative myxomas in the left atrium and right ventricle.
(B) Patient 1 - pre-operative myxomas in the left ventricle. (C) Patient 2 - post-operative recurrent myxoma in the left ventricle 3 months after
the operation.
Figure 2 Identification of cardiac myxomas by MRI. The presence of cardiac myxomas was confirmed by MRI in patient 1. (A) Right ventricle.
(B) Left atrium. (C) Left ventricle.
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ascending aorta cannulation with cardiac arrest. Myo-
cardial protection was achieved by antegrade cardio-
plegia with St. Thomas solution. A 18 × 20 × 20 mm3
myxoma attached to the anterior mitral valve was
removed through an interatrial septum incision
(Figure 4A,B). Five myxomas were discovered in the
right ventricle attached to cardiac muscle. Three myx-
omas measuring 18 × 20 × 20, 20 × 20 × 20, and 18 ×
20 × 22 mm3 were in the inlet area or trabecular
area and were removed through the tricuspid valve
(Figure 4C). The remaining two myxomas measuringFigure 3 Clinical presentation of skin hyperpigmentation. Both patient
(B) Patient 2.6 × 8 × 8 and 8 × 8 × 8 mm3 were in the outlet area
and were removed through a right ventricular outflow
tract incision (Figure 4D). From the left ventricle, two
myxomas (13 × 15 × 15 and 14 × 15 × 16 mm3) at-
tached to the apical portion were removed through a
left ventricular apical incision (Figure 4E,F). In total,
eight myxomas were excised from the patient
(Figure 4G).
During the operation, the aortic cross-clamp time was
110 min and the cardiopulmonary bypass time was 146
min. The patient was in need of assisted mechanical
ventilation for 15.55 h. Patient 1 remained in thes presented with spotty skin pigmentation on their faces. (A) Patient 1.
Table 1 Further evaluation of the two patients
Case 1 (14-year-old male) Case 2 (22-year-old male)
Blood glucose Normal Normal
MRI pituitary examination No sign of pituitary microadenoma was
found in sellar MRI scanning
A low signal shadow with unclear boundary was
found at the lower left medial side of the pituitary
CT adrenal gland
examination
No obvious lesion in the bilateral adrenal
glands was identified




Cortisol: 457.9 nmol/L (8 o’clock), 327.2 nmol/L
(16 o’clock), 197.3 nmol/L (0 o’clock), corresponding
adrenocorticotrophic hormone (ACTH) (8/16/0 o’clock):
18.57 pg/ml; 8.85 pg/ml; <1.0 pg/ml; 24-h urinary free
cortisol (UFC): 309.4 nmol/24 h
Cortisol: 353.4 nmol/L(8 o’clock), 218.6 nmol/L (16 o’clock),
70.8 nmol/L (0 o’clock), adrenocorticotrophic hormone
(ACTH) (8/16/0 o’clock): 41.80 pg/ml; 31.53 pg/ml; 22.73 pg/ml;
24-h urinary free cortisol (UFC): 308.4 nmol/24 h
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stay of 10 days.
The patient’s recovery was uneventful. A postoperative
echocardiograph indicated that no myxomas remained
in any of the cardiac chambers. Follow-ups were per-
formed at 3, 6, and 33 months after surgery. In each
follow-up, echocardiography indicated no myxomas.
The patient was evaluated as being in New York Heart
Association functional class I.
Beijing Ginkgo Wheat Biotechnology Co., Ltd,
Beijing, 100084, China, provided genomic sequencing
of the patient’s DNA in the PRKAR1A gene. The re-
sults indicated the presence of a c.491_492delTG mu-
tation (Figure 5A). The genomic DNA was isolatedFigure 4 Surgical resection of cardiac myxomas from patient 1. Cardia
incision; (B) attached to the anterior mitral valve; (C) through the tricuspid
(E, F) through a left ventricular apical incision. (G) After excision, the myxo
row); left ventricle (the second row); and left atrium (the third row).from the peripheral blood lymphocytes and amplified
by PCR using standard methods with the primers
listed in Table 2. The gel purified PCR products were
then sequenced in both directions on an automated
sequencer (ABI 3700; GinkgoWheat Co. Ltd, Beijing,
China). Nucleotides were numbered in accordance
with the reference sequence for PRKAR1A (GenBank
accession no. NG_007093.3).
Case report 2
The patient reported on above has a 22-year-old brother
who was also diagnosed with multiple cardiac myxomas
in February 2011 and who had undergone surgical treat-
ment in another hospital, the Central Hospital ofc myxomas removed from patient 1 (A) through the interatrial septum
valve; (D) through an incision of right ventricular outflow tract; and
mas grouped by point of origin in the heart. Right ventricle (the first
Figure 5 Genomic sequencing from patient 1 and patient 2. Genomic DNA was sequenced from both patients for mutations in the PRKAR1A
gene: (A) patient 1 - c.491_492delTG; (B) patient 2 - c.491_492delTG; and (C) normal control.
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Table 2 Novel PRKAR1A oligonucleotide sequences for
mutation detection
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patient 2 also had spotty skin pigmentation on his face
(Figure 3B). Primary symptoms were palpitations and short-
ness of breath after activity over the previous 2 years that
had become aggravated over 15 days by sudden syncope.
Ultrasound examination results showed a mural
mass with medium echo (5.7 × 3.4 cm) in the left
atrium, and the base of the mass was at the lower
interatrial septum near the origin of the anterior mitral
valve leaflet; a mural mass with medium echo (7.5 ×
5.1 cm) was found in the left ventricle, and the base of
the mass was wide and located at the lower ventricular
anterior wall; a mural mass with medium echo (3.4 ×
2.5 cm) was found in the right atrium, and the base of
the mass was relatively wide and located at the tra-
becular of the right ventricular anterior wall; and a
mural mass with medium echo (2.2 × 1.4 cm) was
found at the right ventricular outflow tract, and the
base was at the anterior wall. The results of further
evaluations are presented in Table 1.
Patient 2 underwent surgery on 24 February 2011.
Two myxomas were removed from the right ventricle
through the tricuspid valve; a 20 × 25 × 30 mm3 myx-
oma from the inlet area and a 30 × 30 × 30 mm3
myxoma from the outlet area. In the left atrium, one
myxoma measuring 30 × 35 × 40 mm3 was attached
to the fossa ovalis and removed through an interatrial
septum incision. In the left ventricle, a 25 × 30 × 30
mm3 myxoma was attached to the apical area andremoved through an interatrial septum incision and
the mitral valve. The cardiopulmonary bypass time
was 105 min, and the aortic cross-clamp time was
68 min.
Follow-up on patient 2 was initially performed 3
months after surgery. Echocardiography revealed a
10 × 15 × 20 mm3 myxoma remaining in the left ven-
tricle (Figure 1C). At 46-month follow-up, the size of
the myxoma in his left ventricle was considered to be
stable, and the estimated size this time was 9 × 15 ×
21 mm3.
Beijing Ginkgo Wheat Biotechnology Co., Ltd,
Beijing, 100084, China, provided genomic sequencing
of the patient’s DNA in the PRKAR1A gene. The
results indicated that he shared the same c.491_492delTG
mutation, as his sibling patient 1 (Figure 5B).
Conclusions
There are two diagnostic guidelines for Carney com-
plex. In the first, at least two major criteria need to be
present for diagnosis. In the second, one major clinical
manifestation and the presence of one supplemental
criterion is sufficient for diagnosis [2] (Table 3). Patient
1 and his brother had multiple cardiac myxomas,
spotty skin pigmentation, PRKAR1A gene mutation,
and an affected first-degree relative. Therefore, they
meet the established diagnostic guidelines and were di-
agnosed with Carney complex.
The case studies presented here suggest to us these
important points: Myxoma in patients with Carney
complex always has an early onset, but we should be
careful if the patient with multiple myxoma is under 40
years old. The following assessments should be under-
taken: skin exam, ask for family history, or PRKAR1A
gene test if necessary. The recurrence of myxoma is
quite common after surgery. But in case 2, the recur-
rence occurred early, within 3 months after surgery,
and the size of myxoma did not grow with a quite long
follow-up, while case 1 did not have any recurrence.
This may suggest that the most important period is
within 3 months of surgery.
In general, cardiac myxomas occur sporadically as an
isolated left atrial mass attached to the fossa ovalis.
They generally occur between the third and sixth de-
cades of life, and most do not recur after surgical re-
section. However, Carney complex cardiac myxomas
occur in families and usually at considerably younger
ages than non-familial myxomas. Single myxoma asso-
ciated with Carney complex can occur, but most often
there are more than one and they occur in any cardiac
chamber. Following surgical resection, Carney complex
myxomas frequently recur both at the initial resection
site and at distant sites [1]. Both patients had multiple
cardiac myxomas. Patient 2 had a recurring myxoma in




1. Spotty skin pigmentation with a typical distribution (lips, conjunctiva and inner or outer canthi, vaginal, and penile mucosa)
2. Blue nevus, epithelioid blue nevus (multiple)
Myxomas
1. Myxoma (cutaneous and mucosal)
2. Cardiac myxoma
3. Breast myxomatosis or fat-suppressed magnetic resonance imaging findings suggestive of this diagnosis
4. Osteochondromyxoma
Endocrine tumors/overactivity
1. PPNAD or paradoxical positive response of urinary glucocorticosteroids to dexamethasone administration during Liddle’s test
2. Acromegaly due to GH-producing adenoma
3. LCCSCT or characteristic calcification on testicular ultrasonography
4. Thyroid carcinoma or multiple, hypoechoic nodules on thyroid ultrasonography, in a young patient
5. Psammomatous melanotic schwannoma
6. Breast ductal adenoma (multiple)
Supplemental criteria
1. Affected first-degree relative
2. Inactivating mutation of the PRKAR1A gene
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most myxomas, in these cases, the myxomas were at-
tached directly to cardiac muscle and did not have
pedicels.
Carney complex is most commonly due to mutations
in the PRKAR1A gene on chromosome 17q22-q24.
This gene may function as a tumor-suppressor gene
encoding the regulatory subunit type 1-alpha (R1) of
protein kinase A. Recently, mutations in the PRKAR1A
gene were estimated to occur in more than 60% of
Carney complex patients [3]. Approximately 20% of
the families affected with Carney complex have 2p16
mutations. To date, there are at least 117 pathogenic
variants in PRKAR1A that have been identified [4-7].
In this study, we identified a PRKAR1A mutation,
c.491_492delTG, in both patients.
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